Table 1: Recurrence across surveyed HSCT programs.
Monitored
process
(Figure 1)
Overall
frequency
Name of the indicator
Number
of center
using this
indicator
Type of
indicator
Proportion of
cases in
which this
indicator was
implemented
for JACIE
preparation
MANAGEMENT PROCESSES
M1
M1
M1
M1
M2
M2
M2
M3
Quality objectives completed
Number of quality report
Number of quality project achieved
among total projects implemented
per year
Quality management meetings
Conduct of audits
Report of severe adverse events
or accidents
Descriptive statistics activity
Healthcare consultant satisfaction
1/293
1/293
1/32
1/32
outcome
outcome
1/1
1/1
1/293
1/32
outcome
1/1
1/293
8/293
1/32
8/32
outcome
process
1/1
8/8
21/293
16/32
process
14/20
25/293
6/293
8/32
6/32
activity
outcome
22/25
2/6
OPERATING PROCESSES
O2
O2
O2
O2
O2
O3
O3
O3
O3
O3
O3
O3
O3
O3
Proportion of qualified persons for
collection
Number of patients who entered
the program and were finally not
transplanted (autologous PBSCT)
Time to find an unrelated
compatible donor
Origin of the unrelated donor for
allograft per year
Number of confirmation of HLA
typing ordered per patient (case of
allograft with unrelated donor)
Follow-up of infection disease
testing
Hematocrit of collection product
Unprogrammed hospitalisation
(complications) during mobilisation
therapy
Apheresis not performed due to
insufficient mobilization
Number of collection contamined
with polynuclear
Complications during collection
procedure
Quality of collected product not
considering bacterial
contamination
Proportion of persons adressed to
apheresis facility who can be
collected
Apheresis efficiency (criteria varies
in different facilities)
1/293
1/32
process
0/1
1/293
1/32
process
1/1
1/293
1/32
outcome
1/1
1/293
1/32
outcome
1/1
2/293
2/32
process
2/2
1/293
1/32
process
1/1
1/293
1/32
outcome
1/1
1/293
1/32
process
1/1
1/293
1/32
outcome
1/1
2/293
2/32
outcome
2/2
2/293
2/32
process
2/2
2/293
2/32
process
0/2
4/293
3/32
outcome
4/4
10/293
9/32
process
8/10
O3
O3
O4
O5
O5
O5
O5
O5
O5
O5
O5
O5
O5
O6
O6
O6
O7
O8
Positive microbiology in collected
cell products
Collection of HSC/target collection
CD34+ cells reached?
Donor's follow-up
Number of stem cell bags with
problematic freezing procedure
Follow-up of the time to freeze
products after collection
% of poor performance in external
quality control
Date of cell processing
Delay in which quality controls are
made available for CTPs collected
at a distant site from the
processing facility
Follow-up of CTP storage
Monitoring Freezing methods
Request of cryopreserved product
Microbial contamination during
processing
Cell recovery post thawing
Tracking / measuring the rate of
compliance with the information
about diagnosis and treatment in
the outpatient department
Number of patients included in a
clinical research protocol/ number
of diagnosis
Apheresis not performed due to
different criterias(relapse,
progression or insufficient general
state)
Proportion of delayed
chemotherapies in relation with
logistical issues or with patient
status
Proportion of prescribed
investigations in transplanted
patients
11/293
11/32
process
6/11
13/293
13/32
outcome
10/13
1/293
1/32
process
0/1
1/293
1/32
outcome
1/1
1/293
1/32
process
1/1
1/293
1/32
process
1/1
1/293
1/32
outcome
1/1
1/293
1/32
process
0/1
2/293
2/293
2/293
1/32
1/32
2/32
process
outcome
outcome
2/2
2/2
2/2
12/293
11/32
process
7/12
15/293
9/32
process
10/15
1/293
1/32
outcome
0/1
1/293
1/32
outcome
0/1
3/293
1/32
outcome
3/3
1/293
1/32
outcome
0/1
1/293
1/32
outcome
1/1
O8
Invasive fungal infections
2/293
2/32
outcome
1/2
O8
2/293
2/32
process
2/2
2/293
2/32
process
1/2
3/293
4/293
2/32
4/32
outcome
outcome
3/3
4/4
4/293
3/32
outcome
3/4
O8
O8
Days with fever ≥ 38°C
Duration of stay on intensive care
unit
% of CVC related complications
Duration of aplasie
Number of PLT or red cells units
transfused in the first 100 days
post SCT
Incidence of GVHD
Positive blood culture yes/no
4/293
5/293
4/32
5/32
outcome
outcome
2/4
5/5
O8
TRM
23/293
18/32
outcome
20/23
O8
O8
O8
O8
O9
O9
O9
Median time in days until
engraftment (granulocyts,platelets
and neutrophils)
Median survival at 2 years posttransplantation (auto PBSCT) of
patients transplanted during the
last 5 years
Lost to follow-up
Follow up of effectiveness of
quality of care and supportive
treatment post transplantation
TRM at least one year post
transplant
Number of patients hospitalised for
post transplant complication
Overall survival
Relapse rate
Length of hospital stay
O10
Donor satisfaction survey
1/293
1/32
outcome
1/1
O10
O10
Complaints
Patient satisfaction
2/293
12/293
2/32
11/32
outcome
outcome
2/2
8/12
O8
O9
O9
O9
O9
O9
17/293
14/32
outcome
15/17
1/293
1/32
outcome
1/1
1/293
1/32
outcome
0/1
2/293
1/32
process
0/2
3/293
2/32
outcome
3/3
3/293
3/32
outcome
3/3
4/293
5/293
7/293
4/32
4/32
7/32
outcome
outcome
process
3/4
3/5
7/7
SUPPORT PROCESSES
S1
S2
1/293
1/293
1/32
1/32
process
outcome
0/1
1/1
9/293
8/32
process
8/9
S3
S3
Document deficiencies
Publications of medical personal
Training and competencies of
medical and paramedical personal
Infrastructure monitoring
Equipement monitoring
5/293
3/293
5/32
3/32
process
process
2/5
2/3
S4
Budget allogeneic clinical unit
1/293
1/32
process
0/1
1/293
1/32
outcome
1/1
1/293
1/32
process
1/1
S2
S4
S4
Collection of stem cells during WE
or holidays
Costs/ procedure points